Rise and shine, everyone, another busy day is on the way. We can tell by the volume of traffic passing by the Pharmalot campus and the escalating pace at which the official mascot is barking at assorted neighbors and creatures. There is only one thing to do when this happens — fire up the coffee kettle to make some cups of stimulation. Our choice today is Vermont maple walnut, and we invite you to join us. After all, the neurons can always use a little extra help. Meanwhile, here are a few tidbits to help you along, and we hope you have a smashing day and conquer the world. And remember, do keep in touch. We enjoy telegrams and postcards as much as the next person. …
The biotech industry is in shake-out mode after the ranks of public drug developers swelled in recent years amid an IPO boom, Bloomberg News tells us. A scrum for capital among the expanded pool of companies and the make-or-break nature of clinical trials drove a contraction in the number of public biotechs last year, with some scooped up by larger rivals while others shuttered. As the sector stabilizes after last year’s slump, a divergence in fortunes is taking center stage. The total number of publicly traded biotechs contracted in 2022 after years of expansion, according to Wedbush Securities analysts.
The New York Times is taking the European Commission to court over the executive institution’s failure to release text messages between its president Ursula von der Leyen and Pfizer chief executive officer Albert Bourla, Politico reports. The newspaper will face off against European Union lawyers in the bloc’s highest court, arguing that the Commission faces a legal obligation to release the messages, which could contain information on EU deals to purchase billions of dollars worth of Covid-19 doses. The case was lodged on Jan. 25 and published on the European Court of Justice public register on Monday, but no detailed information is yet available online.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect